OrbusNeich has secured the US Patent and Trademark Office (USPTO) grant of additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology.
The US Patent Number 7,803,183 covers a coating on an implantable medical device that has one or more layers of a matrix and incorporated into the matrix are antibodies or antibody fragments that allow for capture in vivo of circulating EPCs.
OrbusNeich intellectual property and technologies vice president Robert Cottone said that this patent further expands OrbusNeich’s intellectual property portfolio of the Genous technology.
"We are continuing to develop our pro-healing technology for our next generation stent platform, which combines both luminal cell capture with abluminal drug elution and is currently in clinical trial evaluation," Cottone said.
OrbusNeich’s patented EPC capture technology, Genous, promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents.
The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.